BioCytics is a biotechnology company focused on advancing cancer immunotherapy through innovative cellular therapies. Their mission encompasses the research and development of novel treatments aimed at various diseases, with a particular emphasis on personalized medicine. The company offers a range of services, including Contract Development and Manufacturing Organization (CDMO) offerings, which support the development and manufacturing of cellular therapies through process and assay development, as well as cGMP manufacturing services. Additionally, BioCytics provides Clinical Research Organization (CRO) services to facilitate early-phase clinical trials for cellular immunotherapy, ensuring that these trials are effectively managed and executed.

The company also operates a biobank that supplies diverse biospecimens for research and development purposes, catering to both industry needs and individual therapeutic requirements. BioCytics is actively involved in clinical trials, with a focus on autologous adoptive cell therapies that utilize the body's own immune cells to target solid tumors. Their pipeline includes several pre-clinical and clinical studies, such as the BioCytics 0001 trial, which investigates the feasibility of harvesting and expanding immune cells and circulating tumor cells. Through collaborations with academic and commercial institutions, BioCytics aims to develop personalized cancer vaccines, leveraging advanced genetic sequencing to identify specific neoantigen targets for individual patients.

United States

BioCytics via the Human Applications Lab is focused on bringing personalized oncology treatments to the market. BioCytics has an ongoing IRB-approved clinical trial (BioCytics 0001; NCT00571389) that allows for the collection and study of blood and tissue samples from consenting cancer patients. We are incubated within Carolina BioOncology - a preferred cancer treatment and Phase I drug testing facility. BioCytics was founded by Dr. John Powderly, MD, medical board certified oncologist and a certified physician investigator (CPI), who is also president of Carolina BioOncology Institute (CBOI).

BioCytics

Company Details